We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

4 hedge funds and large institutions have $2.75M invested in Hepion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 6 → 4 (-2)

39% less capital invested

Capital invested by funds: $4.51M → $2.75M (-$1.76M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$1.39M
2
Morgan Stanley
Morgan Stanley
New York
-$307K
3
Creative Planning
Creative Planning
Kansas
-$1K
4
DADC
D.A. Davidson & Co
Montana
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.29M – – –
HighTower Advisors
2
HighTower Advisors
Illinois
$540K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$180K – – –
Barclays
4
Barclays
United Kingdom
$153K – – –
PFS
5
Prospera Financial Services
Texas
$126K – – –
JP Morgan Chase
6
JP Morgan Chase
New York
$105K – – –
CS
7
Credit Suisse
Switzerland
$78K – – –
Northern Trust
8
Northern Trust
Illinois
$57K – – –
Morgan Stanley
9
Morgan Stanley
New York
$37K -$307K -1 Closed
BlackRock
10
BlackRock
New York
$31K – – –
TSS
11
Two Sigma Securities
New York
$27K – – –
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$26K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$21K – – –
UBS Group
14
UBS Group
Switzerland
$18K – – –
VF
15
Virtu Financial
New York
$17K – – –
ISL
16
Ingalls & Snyder LLC
New York
$11K – – –
Cambridge Investment Research Advisors
17
Cambridge Investment Research Advisors
Iowa
$8K – – –
LPL Financial
18
LPL Financial
California
$8K – – –
FFA
19
First Foundation Advisors
California
$5K – – –
MCIA
20
Mountain Capital Investment Advisors
Colorado
$3K – – –
BWA
21
BDO Wealth Advisors
Florida
$2K – – –
Wells Fargo
22
Wells Fargo
California
$2K – – –
VIA
23
Vantage Investment Advisors
Pennsylvania
$1K – – –
AFM
24
Anson Funds Management
Texas
– -$1.39M -4 Closed
Creative Planning
25
Creative Planning
Kansas
– -$1K – –
1
2

HEPA Hedge Fund Activity: Q3 2017 in Review

4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2017, worth a combined $2.75M — down 39% from $4.51M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of HEPA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Anson Funds Management, exiting entirely with an estimated $1.39M sold.

  • 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2017, down from 6 in Q2 2017.
  • Funds reported $2.75M of Hepion Pharmaceuticals stock for Q3 2017, down 39% quarter-over-quarter.
  • 0 funds opened new Hepion Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -2 holders.
  • The largest Hepion Pharmaceuticals seller in Q3 2017 was Anson Funds Management, an estimated $1.39M sold.

Based on aggregated 13F filings for Q3 2017.